Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May;11(3):394-405.
doi: 10.4168/aair.2019.11.3.394.

Serum Levels of Eosinophil-Derived Neurotoxin: A Biomarker for Asthma Severity in Adult Asthmatics

Youngsoo Lee  1 , Ji Ho Lee  2 , Eun Mi Yang  1 , EunMi Kwon  3 , Chang Gyu Jung  4 , Su Chin Kim  1 , Youngwoo Choi  1 , You Sook Cho  5 , Chang Keun Kim  3 , Hae Sim Park  6
Affiliations

Serum Levels of Eosinophil-Derived Neurotoxin: A Biomarker for Asthma Severity in Adult Asthmatics

Youngsoo Lee et al. Allergy Asthma Immunol Res. 2019 May.

Abstract

Purpose: Eosinophilic inflammation is a key component of severe asthma (SA). However, there has been no reliable serum biomarker for the eosinophilic inflammation of SA. We hypothesized that serum eosinophil-derived neurotoxin (EDN) could predict the eosinophilic inflammation of SA in adult asthmatics.

Methods: Severe asthmatics (n = 235), nonsevere asthmatics (n = 898), and healthy controls (n = 125) were enrolled from Ajou University Hospital, South Korea. The serum levels of EDN and periostin were measured by enzyme-linked immunosorbent assay and compared between severe and nonsevere asthmatics. Their associations with total eosinophil count (TEC) and clinical parameters were evaluated; clinical validation of the K-EDN kit for the measurement of serum EDN was evaluated.

Results: Severe asthmatics were older and had longer disease duration with significantly lower levels of forced expiratory volume in 1 second and methacholine PC20 than nonsevere asthmatics. Significant differences were found in TEC or sputum eosinophil count (%) between the groups. The serum levels of EDN and periostin were significantly higher in severe asthmatics than in nonsevere asthmatics and in healthy controls (all P < 0.05). Although significant correlations were found between serum EDN levels measured by the 2 kits (ρ = 0.545, P < 0.0001), higher correlation coefficients between serum EDN levels measured by the K-EDN kit and TEC were higher (ρ = 0.358, P < 0.0001) than those between serum EDN levels measured by the MBL kit and TEC (ρ = 0.319, P < 0.0001) or serum periostin level (ρ = 0.222, P < 0.0001). Multivariate regression analysis demonstrated that serum EDN levels measured by the K-EDN kit predicted the phenotype of SA (P = 0.003), while 2 other biomarkers did not.

Conclusions: The serum EDN level may be a useful biomarker for assessing asthma severity in adult asthmatics.

Keywords: Eosinophil-derived neurotoxin; asthma; biomarkers.

PubMed Disclaimer

Conflict of interest statement

There are no financial or other issues that might lead to conflict of interest.

Figures

Fig. 1
Fig. 1. (A) Comparison of serum EDN levels measured by the K-EDN kit among severe asthmatics, nonsevere asthmatics, and NCs. (B) Comparison of serum EDN levels measured by the MBL kit between severe asthmatics, nonsevere asthmatics, and NCs.
EDN, eosinophil-derived neurotoxin; NC, normal control.
Fig. 2
Fig. 2. Correlation between the eosinophilic biomarkers in total asthmatics. (A) TEC and serum EDN levels measured by the K-EDN kit. (B). TEC and serum EDN levels measured by the MBL kit. (C) TEC and serum periostin levels.
EDN, eosinophil-derived neurotoxin; TEC, total eosinophil count.
Fig. 3
Fig. 3. (A) ROC curves for the serum EDN levels measured by the K-EDN kit in the prediction of severe asthma in the total asthmatics. (B) ROC curves for the serum EDN levels measured by the MBL kit in the prediction of severe asthma in the total asthmatics.
ROC, receiver operating characteristic; EDN, eosinophil-derived neurotoxin; AUC, area under the curve; CI, confidence interval.
See this image and copyright information in PMC

References

    1. Yoo KH, Ahn HR, Park JK, Kim JW, Nam GH, Hong SK, et al. Burden of respiratory disease in Korea: an observational study on allergic rhinitis, asthma, COPD, and rhinosinusitis. Allergy Asthma Immunol Res. 2016;8:527–534. - PMC - PubMed
    1. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:355–366. - PubMed
    1. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–659. - PubMed
    1. Kim MA, Izuhara K, Ohta S, Ono J, Yoon MK, Ban GY, et al. Association of serum periostin with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2014;113:314–320. - PubMed
    1. Pin I, Freitag AP, O'Byrne PM, Girgis-Gabardo A, Watson RM, Dolovich J, et al. Changes in the cellular profile of induced sputum after allergen-induced asthmatic responses. Am Rev Respir Dis. 1992;145:1265–1269. - PubMed